Navigation Links
Patients now surviving once-fatal immune disease

Individuals who have a rare genetic immune system disorder that prevents them from making antibodies nevertheless appear to be moderately healthy and lead productive lives, according to results of a study by investigators at St. Jude Children's Research Hospital. A report on this study appears in the current online edition of Clinical Immunology.

The study of 41 adults with X-linked agammaglobulinemia (XLA) showed that they can function as relatively healthy, productive individuals, even though they remain vulnerable to chronic, low-grade infections. These individuals had a mean age of 4 years (range 1 month to 53 years) when their diseases were diagnosed; and 27 of the patients had family histories of XLA. The study was based on results of a questionnaire filled out by each participant concerning current and past medical problems and quality of life.

"Until we did this study, there was almost nothing in the medical literature about adults with XLA," said Mary Ellen Conley, M.D., a member of the Department of Immunology at St. Jude and senior author of the report. "In fact, old reports we read stated that the vast majority of these patients have chronic lung disease by age 15. We and other physicians were quite surprised at how well these patients are doing with the proper care."

XLA is a rare disease that is inherited through a mutation in the Btk gene on the X-chromosome--one of the two types of sex chromosomes. Males with this disease have very low levels of infection-fighting proteins called antibodies. Treatment includes aggressive use of antibiotics and replacement of the missing antibodies with gamma globulin.

"Almost all of the adults with XLA had chronic medical problems; however, these problems did not interfere with normal daily activities, and the quality of life in this group was equivalent to that of the general male population of the United States," said Vanessa Howard, R.N., M.S.N., a nurse practitioner for the Immun
'"/>

Source:St. Jude Children's Research Hospital


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
3. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
4. Implanted Devices Detect High-Risk Heart Failure Patients
5. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
6. Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients
7. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
8. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
9. IMF Launches World’s First DNA Database for Myeloma Patients
10. Patients and their doctors have different perceptions about HIV and its treatment
11. Patients to benefit from novel technology revolutionizing high-speed molecular imaging

Post Your Comments:
(Date:11/24/2009)...pening new doors to understanding how sounds assoc...a marine mammal or if they hear it at all. , Th...rs that NASA uses to detect flaws in the space shu... scientists to peek inside the giant head of a wha...onal replicas of a whale,s hearing anatomy using a...
(Date:11/24/2009)...erican College of Medical Toxicology (ACMT) have s...on of the Journal of Medical Toxicology (JMT), t...h 2010. It was previously published by the Univer...edical Toxicology , an international, peer-reviewe...nd practice of medical toxicology. The quarterly ...
(Date:11/24/2009)...ember 24, 2009) New research on bacterial communi...reveals predictable temporal patterns, suggesting ...kers for monitoring climate change in the polar re...eedings of the National Academy of Sciences Early...six rivers shifted synchronously over time, correl...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Cardinal Health Completes Biotech Acquisition 13325 1Cardinal Health Completes Biotech Acquisition 13325 2Gym Class Injuries Up 150 Percent 53471 1Gym Class Injuries Up 150 Percent 53471 2Gym Class Injuries Up 150 Percent 53471 3Medical Services of America Selects Authentidates Inscrybe Healthcare to Standardize Healthcare Order Process Management 53467 1Medical Services of America Selects Authentidates Inscrybe Healthcare to Standardize Healthcare Order Process Management 53467 2Medical Services of America Selects Authentidates Inscrybe Healthcare to Standardize Healthcare Order Process Management 53467 3Medical Services of America Selects Authentidates Inscrybe Healthcare to Standardize Healthcare Order Process Management 53467 4
...an. 16, 2008) -- Two major federal grants have bee...l Medical College in New York City. , Dr. Kennet... million NIH grant from the National Institute on ...effects of a school-based drug-abuse prevention pr... attending New York City middle schools. The study...
...nuary 16, 2008) The latest medications can delay ...e to reverse its devastating effects. This limitat...ers patients maintaining a good quality of life fo...oped by the Georgia Institute of Technology and Em... inexpensive test that could be administered as pa...
... most significant questions facing marine ecologis...iations in the environment are having on the dispe...en oceans to coral reefs. Previously, tracking how...vation by divers on older larvae found near the re...kton. This method did not permit divers to follow ...
Other Biology News:2 federal public health grants awarded to Weill Cornell Medical College 2Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3How baby fish find a home 2
(Date:11/25/2009)...ING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech ...accines, announced today that it executed,a joint ...n) Vaccine,Technology Co., Ltd. (Sinovac Dalian). ...ialize human-use vaccines. Sinovac will contribute...mmercializing world-class vaccines; the,other part...
(Date:11/24/2009)...e in German . , Whether it,s CD packaging, ...io Frequency Identification) are increasingly find...sible to label objects or goods and identify them ...scanner can read and process the data contained in...nder production conditions of up to 100 degrees Ce...
(Date:11/24/2009)...he New York investment bank KTA Capital,s client N...AU$6.7 mil convertible note private placement with...ent was arranged by KTA Capital as Neuren,s exclus... New York (PRWEB) November 23, 2009 -- Th..., LLC ("KTA Capital") has announced that...
(Date:11/24/2009)... REYKJAVIK, Iceland, November 24 /PRNewswire-Firs...day announced that it has received notice from,the... common stock will be,suspended as of November 30,...urities and Exchange Commission, which will remove...ess the company files an appeal to the Nasdaq,List...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) t...arter and year ended December 31, 2008. For the...1 million and a net loss of $22.8 million. Cash a...ber 31, 2008. , , On March 27, the Company filed...h included an audit opinion with a "going concern"...
... Biomedical, Inc., announced today that it will ma... progenitor cells commercially available to the re...otent human embryonic stem cells, ArunA,s hMC line...populations of mesenchymal cells in a feeder free ...com.com/cgi-bin/prnh/20080819/CLTU003LOGO ) , ...
... Catalyst Pharmaceutical Partners, Inc. (Nasdaq: ...s, in-licenses, develops and commercializes prescr...today reported financial results for the fourth qu...lyst made significant progress in 2008," said Patr...t Pharmaceutical Partners. "During the year, we i...
Other Biology Technology:TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results 2TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results 3TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results 4TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results 5ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells 2Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 2Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 3Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 4Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 5Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results 6
Reverse Transcriptase AMV; RNA dependent DNA polymerase from Roche Applied Science
MMLV RT from Invitrogen
Shake 'n' Stack oven - New Model from Thermo Scientific
DNA Polymerase I, E. coli from EPICENTRE Biotechnologies
Biology Products: